How many drugs treat Chronic idiopathic urticaria?

Drug Landscape tracks 8 marketed treatments for Chronic idiopathic urticaria (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chronic-idiopathic-urticaria.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chronic idiopathic urticaria — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic idiopathic urticaria (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic idiopathic urticaria, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xyzal	LEVOCETIRIZINE	Sanofi	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Zyrtec	cetirizine	Generic (originally UCB Pharma)	Second-generation antihistamine	Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2	1995-09-29
Claritin	loratadine	Generic (originally Schering-Plough)	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Desloratadin	Desloratadin	Max Zeller Soehne AG		5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1
Xolair	omalizumab	Roche	Anti-IgE [EPC]	Ig epsilon chain C region
Xolair	Xolair	Taizhou Mabtech Pharmaceutical Co.,Ltd		Ig epsilon chain C region

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Chronic idiopathic urticaria
Generic (originally Hoechst Marion Roussel/Sanofi) · 1 drug in Chronic idiopathic urticaria
Generic (originally Schering-Plough) · 1 drug in Chronic idiopathic urticaria
Generic (originally Schering-Plough/MSD) · 1 drug in Chronic idiopathic urticaria
Generic (originally UCB Pharma) · 1 drug in Chronic idiopathic urticaria
Max Zeller Soehne AG · 1 drug in Chronic idiopathic urticaria
Roche · 1 drug in Chronic idiopathic urticaria
Sanofi · 1 drug in Chronic idiopathic urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd · 1 drug in Chronic idiopathic urticaria

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic idiopathic urticaria:

Cite this brief

Drug Landscape (2026). Chronic idiopathic urticaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-idiopathic-urticaria. Accessed 2026-06-10.

Chronic idiopathic urticaria full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing